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The connexin 31 (Cx31) mutants L135V and L209F are linked to the skin disease 
erythrokeratodermia variabilis et progressiva. We investigated the life-cycle of Cx31 and 
its interplay with co-expressed Cx26, Cx30 and Cx43 in rat epidermal keratinocytes. We 
demonstrated that the apparent half-life of Cx31 was extended compared to Cx43, and 
that Cx31 gap junctions persisted longer at the cell surface. In REKs, Cx31 gap junctions 
were dynamic and the ablation of Cx43 did not prevent Cx31 gap junction formation. 
Furthermore, Cx31 and Cx30 localized to the same gap junctions and exhibited the 
highest correlation coefficient. Lastly, we demonstrated that the L209F and L135V 
mutants did not form gap junctions and induced cell death. Together, our findings suggest 
Cx31 exhibits a longer half-life than most connexins and that the L209F and L135V 
mutants cause EKVP through mechanisms that include the loss of Cx31 gap junction 
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1.0 – Introduction  
 
1.1 – Connexins and gap junctions 
 
Connexins (Cx) are a family of 21 gap junction-forming proteins in humans, named after 
their respective molecular masses (e.g. Cx43 has a molecular mass of 43 kDa) (Laird, 
2006). To date, connexin topology has been studied for Cx26, Cx32 and Cx43, and is 
defined by four transmembrane domains (M1 – M4), two extracellular loops (E1, E2), a 
cytoplasmic loop (CL), and an N-terminal (NT) and C-terminal (CT) facing the 
cytoplasmic area (Zhang and Nicholson 1994; Milks et al. 1988; Yancey et al. 1989; 
Laird and Revel 1990). The transmembrane and extracellular loop domains are highly 
conserved amongst connexin family members, but the cytoplasmic loop and cytoplasmic 
tail domains vary considerably in length and amino acid sequence (Yeager and Harris, 
2007).  These domains govern various gap junction properties including connexin 
trafficking, connexon docking, channel formation and gating (Bai and Wang, 2014; 
Yeager and Harris, 2007). For example, the M3 domain of Cx26 plays a role in gap 
junction function through the regulation of the pore size and, consequently, junctional 
conductance levels (Beahm et al., 2006). Similarly, the M3 domain of Cx43 and Cx50 
also plays a role in gap junction function, likely through channel gating (Beahm et al., 
2006). Furthermore, the NT domain of Cx26 has also been implicated in channel gating 
(Maeda et al., 2009).  
Connexin subunits oligomerize to form hexameric structures, termed connexons, that 
dock with one another to form gap junction channels. At the cell surface, channels 
arrange into tightly packed arrays and are referred to as ‘gap junction plaques’ (Caspar et 
al., 1977; Severs, 1995). These plaques can be composed of a few, or up to thousands of 
gap junction channels that facilitate the exchange of molecules and ions of less than 1 
kDa in mass, such as cAMP, ATP and Ca2+ , to name a few (Goldberg et al., 1999, 2004). 
This exchange of cellular molecules is also known as gap junctional intercellular 
communication (GJIC).  
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1.2 – The life cycle and trafficking of connexins  
 
Connexins are synthesized by endoplasmic reticulum (ER) membrane-bound ribosomes 
and are co-translationally threaded into the ER membrane. Membrane vesicles carrying 
connexin polypeptides bud from the ER and fuse with the Golgi stacks before exiting the 
Golgi apparatus for their final delivery to the plasma membrane (Fig. 1) (Laird, 2006). 
Numerous studies using  brefeldin A (BFA) have elucidated the routing of connexins 
from the ER to the Golgi compartments in multiple cell types including rat epidermal 
keratinocytes, rat mammary tumor cells, and human cervical carcinoma HeLa cells 
(Feldman et al., 1997; Kelly et al., 2015; Laird et al., 1995; Martin et al., 2001). Upon 
treatment with BFA, an ER-Golgi protein transport inhibitor, newly synthesized 
connexins acquire an ER-like distribution pattern and disruption of the Golgi apparatus 
becomes apparent (Feldman et al., 1997; Kelly et al., 2015; Laird et al., 1995; Martin et 
al., 2001). This disruption can be visualized through immunostaining for GM130, a cis-
Golgi resident protein that is involved in the maintenance of the Golgi stacks (Nakamura, 
2010). Subcellular fractionation experiments have been used to detect connexins in the 
ER and Golgi apparatus supporting connexin trafficking via the ER-Golgi pathway 
(Rahman et al., 1993). During connexin trafficking, connexin oligomerization can occur 
in one of two compartments of the secretory pathway; the ER or the trans-Golgi network 
(TGN) (Falk et al., 1997; Koval et al., 1997; Maza et al., 2005; Musil and Goodenough, 
1993).  
In accordance with efficient GJIC regulation, gap junctions are highly dynamic structures 
with fast turnover rates. Hundreds of channels can be internalized at once into double 
membrane vesicles termed connexosomes (Jordan et al., 2001). Such connexosomes were 
frequently observed near lysosome-like structures (Naus et al., 1993) and are believed to 
fuse with lysosomes for degradation. The use of lysosomal inhibitors in vitro increased 
total Cx43 and Cx43 gap junctions further supporting the involvement of the lysosomal 
pathway in connexin degradation (Laing et al., 1997; Qin et al., 2003; Rahman et al., 
1993).  









Figure 1.  
 
Figure 1. 
Laird, Naus & Lampe, 2017
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Fig. 1. Schematic of the typical life cycle of a connexin. Connexins are synthesized in 
the endoplasmic reticulum (ER). Depending on the connexin subtype, oligomerization to 
form connexons can occur either in the ER or trans Golgi network (TGN). Connexons, 
composed of one or more connexin subtypes, are transported to the cell surface where 
they can act as hemichannels or dock with an apposing connexon to form a gap junction 
channel. Gap junctions are internalized into connexosomes and are typically degraded 
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Compared to other transmembrane proteins, connexins have an unusually short half-life 
of 1 – 5 hours as established by pulse-chase studies (Beardslee et al., 1998; Berthoud et 
al., 2004; Fallon and Goodenough, 1981; Laird et al., 1991). While pulse-chase is an 
established technique in determining a proteins half-life, an ‘apparent’ or ‘relative’ half-
life can be determined through protein synthesis inhibition and subsequent analysis of 
protein levels over time. Cycloheximide (CHX) is a commonly used pharmacologic agent 
that inhibits protein synthesis through binding to the 60S ribosomal subunit and blocking 
of the eEF2-mediated translocation step (Schneider-Poetsch et al., 2010). In a recent 
study, CHX treatment was used to conclude that Cx30 had  a prolonged half-life relative 
to Cx43 (Kelly et al., 2015). This was further supported by the persistence of Cx30 gap 
junctions at the cell surface and the persistence of Cx30 in the Triton-insoluble (gap 
junction pool) fraction following 7 hours of BFA treatment (Kelly et al., 2015). Thus, 
CHX and BFA are useful tools for examining connexin trafficking and for determining 
the apparent half-life of connexins. Furthermore, the fact that Cx30 and Cx43 have 
different half-lives raises questions as to whether other connexins would have short or 
long half-lives.  
 
1.3 – The oligomerization and co-assembly of connexins into gap junctions  
 
Connexins are classified into subgroups based on amino acid sequence similarities, with 
a and b being the major subgroups (Koval et al., 2014). Due to their different amino acid 
sequences, a and b connexins rarely form heteromeric connexons. For example, a-Cx43 
and b-Cx26 cannot form heteromeric connexons as deduced by velocity centrifugation 
and affinity purification of histidine-tagged Cx43 (Gemel, 2004). In a variety of cell 
types it has been shown that connexons can be composed of different a connexin family 
members such as Cx50 and Cx46, Cx43 and Cx56, and Cx40 and Cx43 (Berthoud et al., 
2001; Jiang and Goodenough, 1996; Valiunas et al., 2001). Heteromeric connexons can 
also be composed of different b connexin family members such as Cx32 and Cx26, and 
Cx26 and Cx30 (Ahmad et al., 2003; Bevans et al., 1998).  
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Connexin composition largely influences the permeability properties of the gap junction 
channel. In C6 glioma cells, homotypic channels comprised of Cx43 exhibited a 120 – 
160-fold greater selectivity for ADP and/or ATP compared to homotypic Cx32 channels 
(Goldberg et al., 1999). Although the permeability of natural metabolites through 
heterotypic channels has not been investigated, size selectivity can be elucidated through 
the use of exogenous dyes. To this end, Weber and colleagues employed a series of Alexa 
Fluor fluorescent probes in Xenopus oocytes expressing heterotypic or homotypic 
channels (Weber et al., 2004). Heterotypic Cx37/Cx43 channels exhibited lower 
permeability to Alexa 488 (molecular weight (MW) 570 kDa) and Alexa 594 (MW 760 
kDa) compared to homotypic Cx43 channels. Instead, heterotypic Cx37/Cx43 channels 
exhibited permeabilities similar to Cx37 homotypic channels indicating that the 
permeability characteristics of a heterotypic channel may be governed by the more 
restrictive connexin. However, the hypothetical number of connexin channel 
configurations far exceeds the number of configurations that are actually assembled. This 
is due to a couple of limiting factors: 1) a and b connexins are rarely able to co-
oligomerize, and 2) only a limited number of connexins are expressed at a given time in a 
single cell. The spatial and temporal regulation dictate the possible channel 
configurations that, in turn, govern channel permeability characteristics.  
The co-expression of multiple connexin family members can lead to the formation of 
‘heterogenous’ gap junctions where two connexins assemble into a common gap junction 
plaque but do not co-oligomerize. For example, Cx43 and Cx26 formed homotypic 
channels that assembled into discrete domains of a gap junction plaque (Gemel, 2004). 
Recently, Cx30 and Cx43 were also demonstrated to form discrete domains within the 
same gap junctions (Kelly et al., 2015). On the other hand, immunofluorescent studies 
revealed overlapping fluorescence patterns of Cx40 and Cx43 gap junctions suggesting 
colocalization to the same connexons (Gemel, 2004). In fluorescence microscopy studies, 
colocalization is visually determined and thus subjected to the erroneous conclusion that 
serendipitous overlapping fluorescence is biologically relevant and true molecular 
colocalization. To reduce bias, methods of quantitative colocalization analysis can be 
implemented. Pearson’s correlation coefficient (PCC) alongside Costes’ algorithm-
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generated automatic threshold is an effective measure of the degree of correlation 
between two molecules of interest (Costes et al., 2004; Dunn et al., 2011).  
 
1.4 – Epidermal physiology and connexin expression 
 
The skin is the largest organ in the body that serves many functions including protection 
against harmful biological pathogens, chemical substances and physical assaults, while 
preventing water and solute loss (Proksch et al., 2008). The skin is composed of three 
layers; the hypodermis, dermis and epidermis. The hypodermis is comprised of fat and 
loose connective tissue with an abundance of proteoglycans and glycosaminoglycans 
(Wong et al., 2016). The highly vascularized dermis is composed of connective tissue and 
contains hair follicles and sweat glands (Powell, 2006). The avascular epidermis adheres 
closely to the dermis via the basement membrane and is composed mainly of 
keratinocytes arranged into four layers: stratum basale, stratum spinosum, stratum 
granulosum, and the stratum corneum that faces the external environment (Powell, 2006). 
Basal proliferative cells residing in the stratum basale enter a terminal differentiation 
program to give rise to cells in the upper differentiated layers. These basal columnar-like 
cells contain intermediate filaments composed of keratin 14 (K14) and 5 (K5) (Alam et 
al., 2011). When keratinocytes in the stratum basale layer begin their differentiation 
process, the expression of K14 and K5 decreases and is eventually replaced by the 
expression of K1 and K10 in the stratum spinosum  (Alam et al., 2011). Upon reaching 
the stratum corneum, keratinocytes become enucleated, and exhibit a flattened 
morphology with a fully mature cornified envelope. The highly efficient turnover of 
keratinocytes maintains the epidermal barrier function and allows for a complete renewal 
of the epidermis in approximately 28 days (Powell, 2006). Keratinocytes therefore 
require an immense amount of energy to sustain their ongoing differentiation. Due to the 
avascular nature of the epidermis, the delivery of nutrients and metabolites across the 
stratified structure is highly dependent on diffusion and likely GJIC.  
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Keratinocyte differentiation and proliferation are also largely maintained by the presence 
of Ca2+ ions (Hennings et al., 1980). In the epidermis, an outward Ca2+ gradient is found 
across the epidermal layers with a low Ca2+ concentration in the stratum basale and the 
highest Ca2+ concentration in the upper stratum granulosum (Menon and Elias, 1991). In 
the stratum corneum, Ca2+ drops to negligible levels (Menon and Elias, 1991).  The role 
of gap junctions and connexins in Ca2+ maintenance has been demonstrated through the 
Cx26 S17F mouse model for keratitis-ichthyosis-deafness (KID) syndrome. These mice 
displayed epidermal hyperplasia and increased Ca2+ levels in the stratum corneum 
implicating the role of gap junctions and connexins, specifically Cx26, in Ca2+ regulation 
and epidermal maintenance (Garcia et al., 2015). When investigated in vitro, the Cx26 
S17F KID syndrome-linked mutant did not form gap junctions; however, when co-
expressed with Cx43, it aberrantly oligomerized with Cx43 and formed leaky 
hemichannels (Garcia et al., 2015). It was thus proposed that the increased Ca2+ levels 
may be due to the leaky Cx26/Cx43 hemichannels (Garcia et al 2016).  
In keratinocytes, the transcripts of ten connexins has been reported and seven are 
expressed at the protein level including Cx26, Cx30, Cx30.3, Cx31, Cx31.1, Cx37 and 
Cx43, with overlapping expression patterns (Di et al., 2001). To date, mutations in at 
least five of these connexins have been identified in a variety of skin diseases: Cx26, 
Cx30, Cx30.3, Cx31 and Cx43 (Avshalumova et al., 2014). In human epidermis, Cx26 
exhibits a variable distribution in the stratum basale, but is most detectable in the stratum 
granulosum (Di et al., 2001) (Fig. 2). Cx30, Cx31 and Cx43 are also detected in the 
suprabasal layers with their highest expression in the stratum granulosum (Di et al., 
2001). Connexins are expressed at variable levels which are highly regulated to fulfill the 
specific needs of keratinocytes to maintain and/or restore epidermal homeostasis 
(Brandner et al., 2004). For example, during wound healing, the expression of both Cx26 
and Cx30 increases and Cx43 decreases at the wound edges (Brandner et al., 2004). The 
downregulation of Cx43 expression is therefore essential for proper wound healing and 
its persistent expression is associated with chronic, non-healing wounds, such as diabetic 
ulcers (Brandner et al., 2004).  













Figure 2.  
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Fig. 2. Diagram depicting Cx26, Cx30, Cx30.3, Cx31 and Cx43 localization in 
human epidermis. Cx26 exhibits a variable expression pattern in the stratum basale but 
is detected in the stratum granulosum. Cx30, Cx30.3, Cx31 and Cx43 are detected in the 
suprabasal layers with their highest expression in the stratum granulosum. Keratin 5 and 
14 are expressed in the basal cells while keratin 1 and 10 are expressed when basal cells 
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Fig. 3. Connexin mutants cause disease by loss or gain-of-function mechanisms. 
Loss-of-function mutations cause disease via many mechanisms that include; misfolding 
of mutant connexins and triggering of endoplasmic reticulum associated degradation 
(ERAD), retention of mutants in the Golgi apparatus, formation of dead hemichannels or 
gap junction channels, and dysregulated clearing of gap junctions. Gain-of-function 
mutations include aberrant intermixing of mutant connexin subtypes, the formation of 
leaky hemichannels, and dysregulated gap junction channels. Diagram taken from Laird 
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1.5 – Mechanisms linked to connexin mutations  
 
To date, mutations in 5 epidermal connexins have been identified in a variety of skin 
diseases and/or defects: Cx26, Cx30, Cx30.3, Cx31 and Cx43 (Avshalumova et al., 
2014). Each connexin harbors numerous mutations that can alter various aspects of the 
connexin life-cycle including connexin trafficking, oligomerization, half-life, 
degradation, the connexin interactome, and even channel permeability (Fig. 3) (Laird, 
2006). With that in mind, it is not surprising that mutations in one connexin can result in 
different diseases that affect one or more organs. Connexin mutations can result in either 
loss or gain-of-function properties (Fig. 3). Loss-of-function mechanisms include the 
retention of connexins in the ER or Golgi apparatus, the formation of inactive gap 
junction channels or gap junctions with decreased activity. For example, immunostaining 
of EKVP patient tissue sections revealed that the Cx43 E227D and A44V mutants 
exhibited a cytoplasmic localization and failed to form gap junctions (Boyden et al., 
2015). The keratitis-ichthyosis-deafness syndrome-linked Cx26 S17F mutant formed gap 
junction channels with decreased activity and inactive homomeric hemichannels in 
Xenopus oocytes (Lee et al., 2009).  
Connexin gain-of-function mechanisms can include aberrant oligomerization and the 
formation of hyperactive gap junction or hemichannels, or leaky hemichannels. For 
example, Lee and team demonstrated that Cx26 skin disease-linked mutants G12R, D50N 
and N14K in Xenopus oocytes formed hemichannels with increased membrane currents 
(Lee et al., 2009). On the other hand, the Cx26 PPK-linked R75W and Vohwinkels 
syndrome-linked D66H exhibited aberrant oligomerization with Cx43 and formed 
channels with reduced intercellular conductance (Rouan et al., 2001). However, despite 
the identification of various mutants and their mechanism of function, it remains elusive 
which wild type and mutant epidermal connexins co-traffic, co-oligomerize, or co-
assemble. These properties in turn determine the level of GJIC that may lead to a 
disruption in epidermal function.  
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1.6 – Connexins and their link to erythrokeratodermia variabilis et 
progressiva 
 
Erythrokeratodermia variabilis et progressiva (EKVP, Online Mendelian Inheritance in 
Man [OMIM] no. 1332200) is a rare skin disorder classified under the heterogeneous 
group of erythrokeratodermias and is characterized by rough, thickened skin 
(hyperkeratotic plaques) and patches of reddened skin (erythematous) that usually present 
at birth or infancy, but can appear in childhood or adulthood (Ishida-Yamamoto, 2016; 
Richard et al., 2003). However, hair, teeth and nails remain unaffected. The transient and 
migratory erythematous patches can be triggered by stress and temperature changes while 
the symmetrically distributed hyperkeratotic plaques remain fixed (Ishida-Yamamoto, 
2016). Mutations in Cx43, Cx31 and Cx30.3 are associated with EKVP and are generally 
inherited in an autosomal dominant fashion (Ishida-Yamamoto, 2016). In the case of b - 
Cx31, at least fourteen mutations have been identified in EKVP patients (Fuchs-Telem et 
al., 2011; Gottfried et al., 2002; Ishida-Yamamoto, 2016) (Fig. 4). How Cx31 functions 
in the epidermis is poorly understood and our understanding of the life cycle of Cx31 in 
general is limited, as this connexin is not widely expressed in other organs. Other 
connexins, like Cx43, are widely found in human tissues and over 73 mutations in the 
GJA1 gene has been linked to oculodentodigital dysplasia (ODDD) and associated 
developmental defects (Laird, 2006; Paznekas et al., 2009).  
 
1.7 – GJB3 (Cx31) mutations involved in EKVP 
 
In vitro studies have identified defective connexin trafficking as a common characteristic 
in some Cx31 EKVP-linked mutants. For example, the R42P, C86S, G12R and G12D 
mutants exhibited a cytoplasmic localization and induced cell death when overexpressed 
in immortalized NEB1 keratinocytes and HeLa cells (Di et al., 2002). Consequently, it 
has been proposed that cell death induced by ER stress may be an underlying mechanism 
linking EKVP-linked mutants to disease (Tattersall et al., 2009). During acute ER stress, 
expression of the ER chaperone binding immunoglobulin protein (BiP) in the ER 
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increases to accommodate the accumulation of misfolded proteins (Gething and 
Sambrook, 1992). In the case of Cx31 C86S- and R42P-mutant expressing cells, an 
upregulation of BiP was observed with increased cell death. These mutants did not form 
gap junction plaques and instead exhibited a cytoplasmic distribution (Tattersall et al., 
2009). However, not all EKVP-linked Cx31 mutant exhibit the same characteristics or 
intracellular distribution pattern, as a brief study revealed that the Cx31 L209F mutant 
was capable of forming gap junctions in NEB1 keratinocytes (Common et al. 2005).  
 
1.8 – Effects of connexin deficiency in mice   
 
In principle, the overlapping expression patterns of multiple connexin subtypes within a 
common tissue or cell type may allow for possible compensation and protection against 
the loss or mutation of a single member of the connexin gene family. This is 
demonstrated in Cx31-deficient mice, where the epidermis exhibited no observable 
alterations or defects (Plum et al., 2001). While Cx31 gene mutations have also been 
linked to hearing loss in humans (Mhatre et al., 2003), Cx31-deficient mice exhibited no 
hearing impairment, probably due to the co-expression of Cx26 and Cx30 in supporting 
cells of the organ of Corti (Lautermann et al., 1998; Plum et al., 2001). It can be noted 
that compensatory mechanisms do not always entail the increased expression of another 
connexin family member, as one might intuitively predict. For example, a conditional 
Cx26 knockdown in the mammary gland did not affect mammary gland development or 
function, and a decrease in Cx30 expression was observed (Stewart et al., 2014). There 
are also cases in which no compensation occurs following a connexin mutation or 
knockout (Maass et al., 2004; Reaume et al., 1995). This is evidenced in neonatal mice 
harboring a truncated C-terminal mutant of Cx43 where the mice exhibited severe 
epidermal barrier defects (Maass et al., 2004), and in Cx43 null mice that did not survive 
birth due to malformations of the heart (Reaume et al., 1995). While connexin-deficient 
mouse models have provided insight into connexin compensatory mechanisms, in vitro 
studies with the use of keratinocyte cultures would allow for the investigation of gap 
junction function and connexin interaction.  












Figure 4.  
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Fig. 4. Diagram of reported EKVP-linked Cx31 mutants.  The Cx31 polypeptide 
harbors EKVP-linked mutations in the N-terminal domain (NT), transmembrane domains 
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1.9 – Rat epidermal keratinocytes as a model to examine Cx31 in 
keratinocytes 
 
Originally isolated in 1983 by Baden & Kubilus (Baden and Kubilus, 1983), the rat 
epidermal keratinocyte REK cell line is a useful model to examine epidermal connexins 
because, unlike some other epidermal derived cell lines, REKs retain the capacity to 
differentiate. In culture, REKs are able to differentiate and form stratified epidermis, 
termed organotypic epidermis, when cultured on membrane inserts and exposed to an air-
liquid interphase (Pasonen-Seppänen et al., 2001). Mimicking rat epidermis, the 
organotypic epidermis is comprised of a basal cell layer, several suprabasal cell layers, 
and a cornified layer. Additionally, REKs express transcripts for a complement of 
epidermal connexins that includes Cx26, Cx30, Cx30.3, Cx31, Cx37, Cx40, Cx43 and 
Cx45 (Maher et al., 2005), thus providing an opportunity to study the localization and 
gap junction formation of multiple co-expressed connexins. However, REKs typically 
express Cx43 with small amounts of Cx26 protein when differentiated (Maher et al., 
2005).  Furthermore, exogenous expression of fluorescent protein (FP)-tagged Cx43, 
Cx30 and Cx26 is possible in REK cells, all of which have been well characterized in 
other cell types (Berger et al., 2014; Simek et al., 2008; Thomas et al., 2005).   
 
1.10 – Rationale 
 
While the roles of Cx43, Cx26 and Cx30 have been interrogated in keratinocytes, Cx31 
remains poorly studied and it is not clear if this connexin exhibits turnover kinetics like 
Cx43 or the more long-lasting Cx30. Furthermore, the composition of gap junctions 
assembled when Cx31 is co-expressed with Cx43, Cx26 or Cx30 is unclear as these 
connexins may assemble into mutually exclusive gap junction plaques or co-assembly 
into the same gap junctions. In addition, EKVP-linked Cx31 mutants (L209F and L135V) 
have not been well examined in keratinocytes and the mechanism(s) of how missense 
mutations in the gene encoding Cx31 causes skin disease is poorly understood. Thus, it 
remains elusive how the L209F and L135V mutants traffic, and assemble into gap 
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junctions within keratinocytes, and whether these mutants promote cell death. Our lab has 
previously shown that Cx43-reduced epidermis displayed an overall thinner epidermis 
with a thinner stratum corneum, and exhibited increased expression of the differentiation 
markers loricrin and involucrin compared to wild type epidermis (Langlois et al., 2007). 
Furthermore, an inducible cre-mediated deletion of Cx43 mouse model (Cx43Cre-ER(T)/+) 
was generated by Kretz and colleagues to examine the protein levels of co-expressed 
Cx30 and Cx31 (Kretz et al., 2003). In the epidermis of Cx43Cre-ER(T)/+  mice, both Cx31 
and Cx30 levels reached a maximum 2 days after wounding of the  epidermis, as opposed 
to 3 days post-wounding in wild type mice (Kretz et al., 2003).These Cx43-reduced mice 
also exhibited increased Cx31 levels in the epidermis following wounding  (Kretz et al., 
2003) suggesting that Cx31 is also an early responder in wounding. To further investigate 
the interplay between Cx43 and Cx31, in the current study we generated a Cx43-ablated 
REK cell line to examine the intracellular distribution and gap junction formation of 
Cx31 in the absence of Cx43. 
1.11 – Hypothesis  
 
We hypothesized: 
a) Wild type Cx31 exhibits a similar life-cycle as Cx43 in keratinocytes.  
b) The EKVP-linked Cx31 mutants, L209F and L135V, will fail to form gap 
junctions to promote keratinocyte cell death. 
 
1.12 – Objectives 
 
The objectives of this study were:  
1.  To compare the removal rates of Cx31 and Cx43 gap junctions in REKs. 
2. To determine if Cx31 co-assembles to the same gap junctions as Cx26, Cx30 and Cx43 
in REKS. 
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3. To assess the intracellular distribution and consequence of EKVP-linked Cx31 L209F 
and L135V mutants, and the deafness only-linked I141V mutant, when expressed in 
REKs. 
 
2.0 – Materials & Methods 
 
2.1 – Cell culture  
 
Rat epidermal keratinocytes (REKs), originally isolated and characterized by Baden and 
Kubilus were kindly provided by Dr. Vincent Hascall (Cleveland Clinic, Cleveland, OH). 
Cervical cancer cells (HeLa) deficient in connexins were purchased from ATCC 
(Manassas, VA).  All cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (Cat# 11960-044, Life Technologies, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS), 100 units/mL penicillin-streptomycin and 2 mM L-glutamine 
(Cat# 25030-081, Life Technologies), at 37°C and 5% CO2. When 70-90% confluency 
was reached, REKs were passaged using 0.25% trypsin/EDTA (Cat# 325-040-EL, 
Wisent, Saint-Jean-Baptiste, QC) for 5 – 10 minutes at 37°C and 5% CO2.  Cells were 
seeded into 35-mm plastic-bottomed µ-dishes (Cat# 81156, Ibidi, Planegg, BY) for live 
imaging studies or 60-mm plastic tissue culture dishes containing glass coverslips for 
immunocytochemistry studies.  
2.2 – cDNA constructs and transfections 
 
Human Cx31-GFP was a kind gift from Dr. Gabriela Richard (Thomas Jefferson 
University, Philadelphia, PA) and was sequenced for verification. cDNAs encoding 
mouse Cx26 and Cx30 cloned in pBluescript vectors were provided by Dr. Christian C. 
Naus (University of British Columbia, Vancouver, BC). Following amplification from 
the pBluescript vectors, Cx26 and Cx30 cDNAs were cloned into pEGFP-N1 vectors 
(BD Biosciences Clontech, Palo Alto, CA) by Berger and colleagues (Berger et al., 
2014). Rat Cx43 encoded in pBluescript vector was provided by Dr. Eric Beyer 
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(University of Chicago, Chicago, IL). Following amplification from the pBluescript 
vector, Cx43 cDNA was cloned into a pEGFP-N1 vector (BD Biosciences Clontech) by 
Jordan and colleagues (Jordan et al., 1999). 
Human Cx26 and Cx43 and mouse Cx30 cDNA were cloned into pTagRFP-N vectors 
(Evrogen; Cedarlane, Burlington, ON) by Berger and colleagues (Berger et al., 2014). 
Vectors encoding Cx31 mutations (I141V-GFP, L209F-GFP and L135V-GFP) were 
purchased from NorClone Biotech (London, ON). All constructs were sequenced for 
verification. The GFP and RFP tags do not noticeably affect connexin trafficking or gap 
junction formation as previously demonstrated (Berger et al., 2014; Simek et al., 2008; 
Thomas et al., 2005).  
To obtain a transfection efficiency of 60 – 80 %, approximately 400,000 REKs were 
seeded into 60-mm dishes with coverslips and transiently transfected the following day 
with 1 μg of DNA using Lipofectamine 3000 (Invitrogen, Cat# L3000001). For each 
dish, a two-reaction mixture was used during the transfection: reaction 1 mixture 
consisted of 125μL Opti-MEM Reduced Serum Medium (Life Technologies Cat# 31985-
070) and 3.7μL Lipofectamine 3000 reagent; reaction 2 mixture consisted of 250μL opti-
MEM Reduced Serum Medium, 0.5 – 1μg of DNA, and 4μL P3000 reagent. Reaction 1 
and 2 mixtures were combined, gently mixed, incubated for 10 – 15 minutes at room 
temperature, and added dropwise to cells growing in DMEM. For co-transfections, 0.5μg 
of DNA for each construct was used (1μg total). All subsequent experiments were 
performed 24 – 48 hours post-transfection.  
 
2.3 – CRISPR/Cas9 ablation of Cx43 in REKs 
 
To examine the role of Cx43 in REKs, Cx43 protein expression was ablated. With the use 
of WTSI Genome Editing (WGE) Sanger CRISPR Search tool, 3 guide RNAs (gRNA) 
with a protospacer adjacent motif (PAM) sequence were designed within the GJA1 
coding sequence. The following oligonucleotide sequences were designed for gRNA:  
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Guide 1: CACCGTCCAAGCCTACTCCACCGC, Guide 2: 
CACCGCACTCCAGTCACCCATGTC, and Guide 3: CACCGAAGCCTA 
CTCCACCGCTGG. 
Guide 1 was annealed and cloned into a Px458 vector (Cat# 48138, Addgene, Cambridge, 
MA) containing Cas9 for S. pyogenes that creates a double stranded break. Guides 2 and 
3 were each cloned into Px461 vectors (Cat# 48140, Addgene) containing Cas9n (D10A 
nickase mutant) from S. pyogenes that creates a single stranded break, thus limiting off 
target effects. Both Px458 and Px461 vectors encoded a green fluorescent fusion protein 
for identification purposes. Vectors were digested with enzyme BpiI and treated with 
alkaline phosphatase for 30 minutes at 37°C, purified, and mixed with the appropriate 
gRNA oligonucleotides. Vectors and oligonucleotides were annealed for 30 minutes at 
37°C and 5 minutes at 95°C and ligated at room temperature for 4 – 5 hours. Ligated 
products were subcloned into pUC19 plasmids containing an ampicillin resistance gene 
and transformed into One Shot™ Stbl3™ Chemically Competent E. Coli cells (Cat# 
C7373-03, Thermo Fisher Scientific, Waltham, MA) following product protocol. 
Successfully cloned cells resistant to ampicillin were selected and DNA was extracted 
using QIAprep Spin Miniprep Kit following product protocol (Cat# 27106, Qiagen, 
Hilden, NW). Transfections of gRNAs were completed using Lipofectamine 2000 
Reagent (Cat# 11668019, Thermo Fisher Scientific), following product protocol. REKs 
were grown to a confluency of 50-70% and transfected with a total of 2μg DNA of Guide 
1. For co-transfection of Guide 2 and Guide 3, 1μg DNA of each construct was used (2μg 
total). Cells successfully expressing the gRNA were single-cell fluorescence activated 
cell sorted (FACS) 48 hours later into 96-well plates and cultured in DMEM at 37°C and 
5% CO2. Approximately 1 week later, cells that survived and grew into a small colony 
were selected for trypsinization and subcultured into a 25cm2 flasks for further 
propagation. Three Cx43-ablated clones were generated and Cx43 ablation was 
confirmed through Western blotting and immunolabeling for Cx43 (minimum of 3 
times).  Since no differences in cellular morphology or K14 distribution was observed 
between all three Cx43-ablated clones, we combined these clones to form a Cx43-ablated 
multiclone cell line for subsequent Cx31-GFP expression studies. 
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2.4 – Live cell time-lapse imaging  
 
Approximately 200,000 REKs were seeded into 35-mm optical grade plastic-bottomed 
dishes (Cat# 81156, Ibidi) and transfected the following day with 0.5μg of Cx31-GFP 
DNA construct. Approximately 24 hours post-transfection, dishes were mounted onto a 
Zeiss LSM 800 confocal microscope within a 37°C heated chamber containing 5% CO2. 
Using a 63x oil immersion lens, images were acquired every 20 – 30 seconds for up to 30 
minutes. Cx31-GFP was excited with a 488 nm argon laser and emitted fluorescence was 
collected through a 500-550 nm band pass filter. Fluorescence images and differential 
interference contrast (DIC) images were acquired simultaneously and superimposed. A 
minimum of 40 Cx31-GFP gap junctions were examined in 8 live cells.  
2.5 – Immunocytochemistry and immunofluorescence imaging 
 
Cells were fixed with 10% neutral buffer formalin (Cat# HT501128, Sigma, St. Louis, 
MO) for 15-18 minutes at room temperature and permeabilized and blocked with 0.1% 
Triton-X100 in 2% bovine serum albumin (Cat#A2153, Sigma) in phosphate-buffered 
saline (PBS) for 1 hour at room temperature. The primary antibodies used include: 1:400 
rabbit polyclonal anti-Cx26 (Cat# 51-2800, Life Technologies), 1:400 rabbit polyclonal 
anti-Cx30 (Cat# 71-2200, Life Technologies), 1:500 rabbit polyclonal anti-Cx43 (Cat# 
C6219, Sigma-Aldrich), 1:200 mouse polyclonal anti-cytokeratin 14 (Cat# MS-115-P, 
Thermo Fisher Scientific,), 1:200 rabbit polyclonal anti-keratin 10 (Cat# PRB-159P, 
Covance, Princeton, NJ), 1:1500 rabbit polyclonal anti-cleaved caspase 3 (cc3) (Cat# 
C8487, Sigma,), 1:500 mouse monoclonal anti-GM130 (Cat# 610822, BD Transduction 
Laboratories), 1:500 mouse monoclonal anti-PDI (Cat# SPA-891, Enzo Life Sciences, 
Ann Arbor, MI), and 1:500 rabbit polyclonal anti-GRP78/BiP (Cat# G8918, Sigma). The 
secondary antibodies used were a 1:500 dilution of Alexa-488-conjugated anti-rabbit 
(Cat# A11017, Life Technologies) and a 1:500 dilution of Alexa-555-conjugated anti-
rabbit (Cat# A-21428, Thermo Fisher Scientific). Cells were incubated with 1:1000 
Hoechst 33342 (Cat# H3570, Molecular Probes, Eugene, OR) for 10 minutes at room 
temperature, mounted with Airvol (15% polyvinyl alcohol, 33% glycerin, and 0.1% 
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sodium azide), and imaged using a Zeiss LSM 800 confocal Airyscan microscope 
equipped with ZenWorks software. Images were acquired using a 40x oil or 63x oil 
immersion objective.  
As a positive control for anti- Cx30, Cx26 and K10 antibody labeling, REKs expressing 
Cx30-RFP, normal rat kidney (NRK) cells expressing untagged Cx26, and wild type 
mouse epidermis were fixed, permeabilized, blocked, and incubated with the appropriate 
primary antibodies, respectively. All positive control samples were subsequently detected 
using Alexa-488-conjugated secondary antibody.  
For studies expressing mutant proteins, 4 – 5 images were captured with the 20x 
objective, blinded, and a minimum of 300 cells for Cx31-GFP, I141V-GFP, L209F-GFP 
and L135V-GFP expressing cells were quantified. A one-way ANOVA was performed 
on the means of 3 biological replicates.  
2.6 – Connexin co-localization analysis 
 
REKs co-expressing Cx31-GFP and Cx26-RFP, Cx31-GFP and Cx30-RFP, and Cx31-
GFP and Cx43-RFP were imaged using a 63x oil immersion objective. Images were 
acquired through 15 Z-stack slices with each slice being acquired at approximately 0.2 
µm intervals (approximate intervals were determined through the ‘optimal section’ 
function in Zeiss software). Image stacks were superimposed for co-localization analysis. 
Use of the ‘range indicator’ function ensured that all gap junctions were captured with 
negligible pixel saturation. Using the ZenWorks co-localization software, regions of 
interest (ROIs) were drawn around each gap junction and a scatterplot of red and green 
pixels (representing the 2 co-expressed connexins) were generated. The Coste’s 
algorithm generated an automatic threshold and the Pearson’s correlation coefficient 
(PCC), a statistic for quantifying colocalization, was computed. A minimum of 60 gap 
junctions were analyzed for each connexin pair and a one-way ANOVA was performed 
on the means of 3 biological replicates. A p value of <0.05 was considered significant.  
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2.7 – Cell lysates and immunoblotting 
 
Cell lysates were prepared with 2x IP lysis buffer (2% Triton X-100, 300mM NaCl, 
20mM Tris, 2mM EDTA, 2mM EGTA, 1% NP-40, pH 7.4) containing 100 mM NaF, 
100 mM sodium orthovanadate and a proteinase inhibitor mini-EDTA tablet. Protein 
content was quantified using a bicinchoninic acid assay kit (Cat# 23225, Thermo Fisher 
Scientific,). 25-30 μg of total protein was loaded in each lane, and separated on 10% 
SDS-PAGE gels, and transferred onto nitrocellulose membranes using the iBlot® dry-
transfer system (Invitrogen).  Membranes were blocked in 3% BSA (Cat#800-095-QG, 
Wisent) in PBS-Tween 20 (PBST) for 1 hour at room temperature or overnight at 4°C. 
The following primary antibodies were used: 1:5000 dilution of rabbit polyclonal anti-
Cx43 (Cat# C6219, Sigma-Aldrich), 1:1000 dilution of mouse monoclonal anti-GFP 
(Cat# MAB3580, Millipore, Burlington, MA) and 1:5000 dilution of mouse anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cat# MA374, Millipore). The 
following secondary antibodies used were as follows: a 1:10000 dilution of goat anti-
mouse Alexa Fluor 680 (Cat#A21057, Life Technologies) and a 1:10000 dilution of goat 
anti-rabbit IRDye 800 (Cat# 611-132-002, Rockland Immunochemicals, Pottstown, PA). 
Protein bands were visualized using Odyssey LiCor infrared imaging system. For 
cycloheximide experiments, band intensities were normalized to 0-hour timepoint and a 
two-way ANOVA was performed on the means of 3 biological replicates. Densitometry 
units are displayed ±SEM and a p value of <0.05 was considered significant. 
 
2.8 – Drug treatments 
 
To block ER-Golgi protein transport, Cx31-GFP expressing REKs growing on glass 
coverslips were treated with 4µg/mL of brefeldin A (Cat# B5936, Sigma) in DMEM for 
up to 6 hours at 37°C and 5% CO2. At 0, 0.5, 1, 2, 4 and 6 hours of treatment, cells were 
fixed and immunolabeled for Cx43 and GM130. Treatment was removed after 6 hours 
and cells were washed twice with DMEM before incubating in DMEM for 2 hours at 
37°C and 5% CO2. A minimum of 5 images were captured at each treatment time point 
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and the number of cell-cell interfaces that expressed Cx43 and Cx31 gap junctions were 
quantified for each treatment time in a fashion where the researcher was blinded to the 
treatment. Only Cx31-GFP positive cell pairs or clusters were considered; a minimum of 
25 cell-cell interfaces were quantified for each biological replicate and a	 two-way	
ANOVA	was	performed	on	the	means	of	3	biological	replicates.	Data	are	represented	as	
the	proportion	of	Cx31-GFP	expressing	REKs	that	express	gap	junctions	±SEM	and	a p 
value of <0.05 was considered significant.	
	
For the inhibition of protein synthesis, Cx31-GFP expressing REKs grown in dishes with 
and without coverslips were treated with 10µg/mL of cycloheximide (Cat# C6255, 
Sigma) in DMEM for up to 6 hours at 37°C and 5% CO2.  At 0, 0.5, 1, 2, 4, and 6 hours 
of treatment, lysates were collected for immunoblotting. In other experiments, cells were 
treated with 0.5µg/mL staurosporine (Cat# S6942, Sigma) in DMEM for 5 hours at 37°C 
and 5% CO2 to induce apoptosis as a positive control for immunolabeling of cleaved 
caspase 3 (cc3). 
 
3.0 – Results  
 
3.1 – Both Cx43 and Cx31-GFP form gap junctions when expressed in 
REKs  
 
 To characterize the endogenous connexins expressed in a keratinocyte cell model, rat 
epidermal keratinocytes (REKs) were cultured to confluency and immunolabeled for 
Cx43, Cx30 and Cx26 (Fig. 5A). Numerous Cx43 gap junctions were detected at cell-cell 
appositions, as evidenced by the punctate structures (arrows, Fig. 5A).  However, no 
Cx30 or Cx26 gap junctions were detected at cell-cell appositions.  As a positive control 
for antibody reactivity, REKs expressing Cx30-RFP and normal rat kidney (NRK) cells 
expressing Cx26 were immunolabeled for Cx30 and Cx26, respectively (insets, Fig. 5A). 
Connexin-deficient HeLa cells were immunolabeled for Cx43, Cx30 and Cx26, and as 
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expected, no immunostaining was detected (Fig. 5A). Unfortunately, no anti-Cx31 
antibody was available to test for the endogenous expression of Cx31 which is the 
connexin of central focus in the current study.  
To circumvent the inability to examine endogenous Cx31 in REKs, we chose to examine 
the life cycle of Cx31 by tagging it with GFP (Cx31-GFP) and exogenously expressing it 
in these keratinocytes. In REKs, Cx31-GFP localized to punctate structures, reminiscent 
of gap junctions, at cell-cell appositions (arrows, Fig. 5B). To compare and confirm that 
our Cx31-GFP formed punctate structures similar to other well characterized GFP-tagged 
connexins (Berger et al., 2014; Simek et al., 2008; Thomas et al., 2005), GFP-tagged 
Cx30, Cx26 and Cx43 were expressed in REKs., Cx30-GFP, Cx26-GFP and Cx43-GFP 
formed gap junction plaques (arrows, Fig. 5B). To confirm that Cx31-GFP migrates at 
the predicted molecular weight in SDS-PAGE, REK expressing Cx31-GFP lysates were 
immunoblotted for GFP as a means of detecting the fusion protein (Fig. 5C). As negative 
controls, untransfected REK and HeLa lysates were used. The predicted molecular 
weight of Cx31-GFP is 58 kDa, however, immunoblotting revealed a band of 46 – 48 
kDa (Fig. 5C). This apparent discrepancy may be due to partial proteolysis and is 
commonly observed with other connexins (Willebrords et al., 2016). Together, these data 
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Fig. 5. Both Cx43 and Cx31-GFP form gap junctions in REKs. (A) REKs were 
immunolabeled for Cx43, Cx30 and Cx26 and stained with Hoechst (blue) to denote 
nuclei. Numerous endogenous Cx43 gap junctions were detected at sites of cell-cell 
appositions but no Cx26 or Cx30 gap junctions were detected. As a positive control for 
antibody reactivity, REKs expressing Cx30-RFP gap junctions, and NRK cells expressing 
Cx26 gap junctions, were immunolabeled for Cx30 and Cx26, respectively (arrows, 
insets). Connexin-deficient HeLa cells were immunolabeled for Cx43, Cx30 and Cx26 as 
a negative control. (B) REKs transiently expressing GFP-tagged Cx26, Cx30, Cx31 and 
Cx43 (green) were fixed and stained with Hoechst (blue) to denote nuclei. All four 
connexins formed gap junctions, to varying degrees, at sites of cell-cell appositions 
(bottom magnified panels, arrows). (C) REKs expressing Cx31-GFP were immunoblotted 
for GFP as a means of detecting Cx31-GFP levels. HeLa and wild type REK lysates were 
used as a negative control. All scale bars in (A) = 20 𝜇m, (B) (including magnified 
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3.2 – Cx31-GFP exhibits different localization patterns when co-expressed 
with Cx26, Cx30 and Cx43 
 
Since keratinocytes co-express multiple connexins, we examined the co-distribution and 
co-localization of Cx31-GFP with Cx26-RFP, Cx30-RFP, or Cx43-RFP in REKs. In 
general, Cx31-GFP formed gap junctions with all three tested connexins.  (Fig. 6).  Cx31-
GFP and Cx43-RFP localized to the same punctate structures but formed domains that 
were visually distinguishable from one another (top panel, arrows, Fig. 6A). Cx31-GFP 
and Cx43-RFP gap junctions exhibited a PCC value of 0.2 suggesting that, while they 
may occupy the same gap junction plaques, they are not likely fully intermixing within 
the same connexons (Fig. 6B). Cx31-GFP and Cx30-RFP localized to the same punctate 
structures and exhibited overlapping distribution patterns (middle panel, arrows, Fig. 5A). 
Cx31-GFP and Cx30-RFP gap junctions exhibited a PCC value of 0.5 suggesting that 
they were more extensively colocalized within the same gap junction plaques (Fig. 6B). 
Cx31-GFP and Cx26-RFP also localized to the same punctate structures and mostly 
formed discrete domains from one another (bottom panel, arrows, Fig. 6A), but on rare 
occasions, they exhibited overlapping distribution patterns (arrowhead, Fig. 6A). 
Generally, Cx31-GFP and Cx26-RFP gap junctions exhibited a PCC value of 0.37 
suggestive of considerable overlap within the gap junction structure (Fig. 6B). 
3.3 – Cx43 ablation and effect on Cx26 and Cx30 expression in REKs 
differentiation   
 
Since Cx43 is highly expressed within REKs, we assessed whether Cx43 ablation would 
drive the expression of other keratinocyte connexins, particularly, Cx26 or Cx30. Using 
CRISPR/Cas9 strategies we ablated Cx43 and isolated three separate clones, which were 
validated by immunofluorescence labeling and immunoblotting for Cx43 (Fig. 7A, B). In 
Cx43-ablated REKs, Cx26 and Cx30 gap junctions were not detected similar to what we 
had observed in wild type REKs (Fig. 7C).  
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Fig. 6. Cx31-GFP gap junctions exhibit different co-distribution patterns with Cx26, 
Cx30 and Cx43. (A) REKs co-expressing Cx31-GFP (green) with RFP-tagged Cx43, 
Cx30 or Cx26 (red) were stained with Hoechst (blue) to denote the nuclei. Cx31-GFP 
formed distinct domains from Cx43-RFP (magnified top panel, arrows) and Cx26-RFP 
(magnified bottom panel, arrows), but exhibited overlapping distribution patterns with 
Cx30-RFP (magnified middle panel, arrows). On rare occasions, Cx31-GFP exhibited 
overlapping distribution patterns with Cx26-RFP (magnified bottom panel, arrowhead). 
Corresponding scatterplots of red and green pixel intensities were generated from the co-
assembled gap junctions. (B) The Coste’s algorithm generated an automatic threshold and 
computed the Pearson’s correlation coefficient (PCC) between the two fluorescence 
channels. Cx31-GFP and Cx43-RFP gap junctions were assigned a lower PCC value 
(PCC= 0.2) compared to Cx31-GFP and Cx30-RFP gap junctions (PCC = 0.5). Cx31-
GFP and Cx26-RFP gap junctions were assigned a PCC value of 0.37. Data are 
represented as average PCC values ±SEM. **p< 0.01, N=3 separate experiments. Scale 
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Fig. 7. Cx26 and Cx30 gap junctions were not detected in Cx43-ablated REKs. 
Ablation of Cx43 in REKs was achieved using a CRISPR/Cas9 strategy and clones were 
validated through (A) immunolabeling and (B) immunoblotting for Cx43; N=3. (C) 
Cx26, Cx30 and K10 immunolabeling were not detected in Cx43-ablated REKs, similar 
to wild type REKs. In Cx43-ablated REKs, the immunolabeling pattern of K14 did not 
change compared to wild type REKs.  As positive controls, wild type mice epidermis was 
immunolabeled for Cx30 and K10, and Cx26 expressing NRK cells were immunolabeled 
for Cx26 (insets). Cells were stained with Hoechst (blue) to denote the nuclei. C1, C2 and 
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Our laboratory has previously shown that a reduction in Cx43 expression led to abnormal 
epidermal differentiation in vitro with an overall increase in loricrin and involucrin 
indicative of keratinocytes becoming more differentiated (Langlois et al., 2007). 
Therefore, to assess whether the complete ablation of Cx43 would trigger keratinocyte 
differentiation, we immunolabeled Cx43-ablated REK monolayers for K10 (indicative of 
more differentiated cells) and K14 (indicative of undifferentiated cells). K10 was not 
detected in our Cx43-ablated REKs, similar to wild type REKs (Fig. 7C). Furthermore, 
the immunolabeling pattern of K14 in Cx43-ablated REKs was observed to be the same 
as that in wild type REKs. Thus, the loss of Cx43 does not trigger either the co-
expression of other connexin family members or promote expression of the 
differentiation marker K10 in REKs. 
3.4 – Cx31 gap junctions are highly dynamic and ablation of Cx43 does not 
prevent their formation in REKs  
 
To assess whether Cx43 modulates the distribution and gap junction formation of Cx31 
in REKs, Cx31-GFP was expressed in Cx43-ablated REKs. Cx31-GFP localized to 
numerous punctate structures at cell-cell appositions similar to those observed in wild 
type REKs (arrows, Fig. 8). In living REKs, Cx31-GFP gap junctions consistently 
underwent remodeling. Many gap junctions were capable of undergoing fission and 
fusion events within a span of 5 minutes (circle, Fig. 9). Fission events were typically 
observed to occur within 3 minutes; the subsequent fusion process with a neighboring 
gap junction typically occurred within 1 minute. The remodeling of gap junctions was not 
due to artefactual movement of the cell or photobleaching since consistent fluorescence 
intensity and positioning was observed in another gap junction (black arrows, Fig. 9) 
within the imaging field. Given that the Cx31-GFP gap junctions in Cx43-ablated REKs 
were similar to those in wild type REKs, we did not pursue any examination of Cx31-
GFP dynamics in live Cx43-ablated REKs. Overall, we observed that Cx31-GFP gap 
junctions are dynamic.  
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 Fig. 8. Cx31-GFP form gap junctions in Cx43-ablated REKs. Wild type and Cx43-
ablated REKs transiently expressing Cx31-GFP (green) were fixed and stained with 
Hoechst (blue) to denote nuclei. Cx31-GFP formed numerous gap junctions at cell-cell 
































Figure 9.  
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Fig. 9. Cx31-GFP gap junctions exhibit remodeling in REKs. In living REKs, Cx31-
GFP gap junctions underwent consistent remodeling. A segment of a gap junction was 
observed to undergo a fission and fusion event with a neighboring gap junction within a 
span of 5 minutes (red circles). The remodeling of gap junctions was not due to 
photobleaching or artefactual movement since consistent fluorescence intensity was 
observed in another gap junction within the imaging field (black arrows). Yellow 
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3.5 – Cx31-GFP gap junctions persist at the cell surface longer than Cx43 
gap junctions 
 
Since Cx30 gap junctions were observed to be long-lived at the cell surface compared to 
Cx43 gap junctions (Kelly et al., 2015), we assessed whether the removal rates of Cx31-
GFP from the cell surface would also differ from that of Cx43. Cx31-GFP expressing 
REKs were treated with BFA for up to 6 hours and then allowed to recover without drug 
treatment for 2 hours (Fig. 10). Dissociation of the Golgi apparatus upon BFA treatment 
was verified through immunolabeling of GM130, a resident protein of the Golgi 
apparatus (Fig. 10A). The number of Cx31-GFP-positive cell pairs or clusters with gap 
junctions were quantified throughout the treatment period and following treatment 
removal (Fig. 10B). After 4 and 6 hours of BFA treatment, Cx43 immunoreactivity at the 
cell surface was noticeably reduced. Cx31-GFP gap junctions were also reduced after 6 
hours of treatment but were still more numerous than Cx43 gap junctions. Loss of gap 
junctions at the cell surface was not likely due to drug cytotoxicity as the effects of BFA 
were reversible since Cx31-GFP and Cx43 gap junctions were readily observed 2 hours 
after BFA washout suggesting that the cells were recovering from the BFA block.  These 
findings suggest that Cx31-GFP gap junctions have a longer residence time at the cell 
surface compared to Cx43 gap junctions.  
3.6 – Cx31-GFP exhibits a longer apparent half-life compared to Cx43 
 
Next, we assessed the half-life of Cx31-GFP relative to Cx43 in REKs after 
cycloheximide inhibition of protein synthesis.  (Fig. 11). After 2, 4 and 6 hours of protein 
synthesis inhibition, Cx43 levels were significantly reduced (Fig. 11A). In contrast, 
Cx31-GFP levels remained relatively unchanged even after 6 hours of protein synthesis 
inhibition (Fig. 11A). Additionally, both Cx31-GFP and Cx43 levels remained prominent 
during the 6-hour treatment suggesting that the drug treatment may have slowed overall 
protein degradation due to the effects of CHX on the cell’s degradation machinery (Fig. 
11B).  
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Fig. 10. Cx31-GFP gap junctions persist at the REK cell surface longer then Cx43. 
(A) Cx31-GFP (green) expressing REKs were treated with 4 µg/mL of BFA for up to 6 
hours. At the 0, 0.5, 1, 2, 4, 6-hour time points, and after washout (2hrs after BFA 
removal), cells were fixed, immunolabeled for Cx43 (red), and stained with Hoechst 
(blue) to denote the nuclei. Dissociation of the Golgi apparatus upon BFA treatment was 
verified through immunolabeling of GM130, a resident protein of the Golgi apparatus. 
(B) The number of Cx31-GFP positive cells pairs or clusters with gap junctions were 
quantified throughout the treatment period and following treatment removal. Cx43 gap 
junctions were less prevalent after 4 and 6 hours of treatment and Cx43 was mostly found 
in intracellular compartments. Cx31-GFP gap junctions decreased after 6 hours but were 
still more prevalent than that of Cx43 gap junctions and displayed an intracellular 
localization in some cells. Data are represented as the proportion of Cx31-GFP 
expressing REKs that express gap junctions ±SEM. A two-way ANOVA was performed 
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Fig. 11. Cx31-GFP exhibits a longer apparent half-life compared to Cx43. (A) Cx31-
GFP expressing REKs were treated with 10 µg/mL of cycloheximide (CHX) for up to 6 
hours. At 0, 0.5, 1, 2, 4, 6-hour time points, lysates were collected and immunoblots were 
labeled for GFP, Cx43 or GAPDH. Cx43 levels were reduced after 2, 4 and 6 hours of 
treatment while Cx31-GFP levels remained unchanged. (B) Further quantification 
revealed that Cx43 levels gradually declined over time while Cx31-GFP remained 
relatively unchanged. Data are represented as densitometry units ±SEM and a two-way 
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3.7 – The Cx31 L209F and L135V mutants are defective at assembling gap 
junctions in keratinocytes and HeLa cells 
 
To assess whether EKVP-linked mutations in Cx31 would affect the trafficking, 
distribution and gap junction formation of Cx31, the L209F and L135V mutants, along 
with the deafness only-linked I141V mutant, were expressed in REKs (Fig. 12A). In wild 
type REKs, Cx31 and the I141V mutant formed gap junctions at the cell surface (arrows) 
while the L209F and L135V mutants were confined to intracellular compartments (Fig. 
12A). To assess whether the Cx31 mutations would affect their trafficking and gap 
junction formation differently in the absence of Cx43, the Cx31 mutants were expressed 
in Cx43-ablated REKs. Cx31 and the I141V mutant formed gap junctions (arrows) while 
the L209F and L135V mutants localized to intracellular compartments, similar to the 
results found when these mutants were expressed in wild type REKs (Fig. 12A). To 
assess whether the Cx31 mutants would exhibit different characteristics in other epithelial 
derived cells, the Cx31 mutants were also expressed in HeLa cells (Fig. 12B). Similarly, 
Cx31 and the I141V mutant formed numerous gap junctions (arrows) while the L209F 
and L135V mutants were found in intracellular compartments. It was notable that all cells 
that expressed the L209F and L135V mutants exhibited evidence of cytotoxicity, 
rounding in appearance with evidence of condensed nuclear material.  
3.8 – The EKVP-linked mutants induce morphological cell changes and cell 
death 
 
Since the L209F and L135V mutant-expressing cells exhibited cell shrinkage and 
condensed nuclei, we immunolabeled for cleaved caspase 3 (cc3) to determine whether 
the mutant-expressing cells were undergoing early-stage apoptosis (Fig. 13). The L209F 
and L135V mutant-expressing cells exhibited cell shrinkage and condensed nuclei and 
immunolabeled for cc3 (Fig. 13A). The EKVP-linked mutants exhibited increased cc3 
labeling compared to the Cx31 and I141V mutant-expressing cells (Fig. 13B). To 
determine whether apoptosis was induced by ER stress, we immunolabeled for BiP (Fig. 
14). The Cx31 L209F and L135V mutant-expressing cells did not exhibit greater BiP 
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staining, but rather, less BiP staining than the neighboring untransfected cells, as well as 
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Fig. 12. EKVP-linked mutants are defective at assembling gap junctions. (A) GFP-
tagged Cx31, as well as L209F, L135V and I141V mutants (green) were expressed in 
wild type and Cx43-ablated REKs, immunolabeled for Cx43 (red) and stained with 
Hoechst (blue) to denote nuclei. Wild type Cx31 and the I141V mutant formed numerous 
gap junctions in REKs and Cx43-ablated REKs (white arrows) while the L209F and 
L135V mutants exhibited an intracellular localization pattern. In REKs, wild type Cx31 
and the I141V mutant exhibited partial colocalization with Cx43 (arrows). (B) GFP-
tagged Cx31, and L209F, L135V and I141V mutants (green) were also expressed in 
connexin-deficient HeLa cells and stained with Hoechst (blue) to denote nuclei. Wild 
type Cx31 and the I141V mutant formed numerous gap junctions in HeLa cells while the 
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Fig. 13. EKVP-linked mutants induce morphological changes and cell death. 
(A)Wild type and Cx43-ablated REKs expressing GFP-tagged Cx31, as well as L209F, 
L135V and I141V mutants (green) were immunolabeled for cleaved caspase 3 (red) to 
reveal cells undergoing apoptosis. Cells were stained with Hoechst (blue) to denote 
nuclei. Cells were treated with 0.5 µg/mL staurosporine for 5 hours as a positive control 
for cells undergoing apoptosis. The L209F and L135V mutant-expressing cells exhibited 
cell shrinkage and condensed nuclei.  (B) The number of GFP and cc3 positive cells were 
quantified and the L209F and L135V mutant-expressing cells exhibited apoptosis 
compared to the Cx31 and I141V-expressing cells. Data are represented as % of GFP 
positive cells labeled for cc3 ±SEM and a one-way ANOVA was performed on the 
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Fig. 14. EKVP-linked mutant-expressing cells exhibit less BiP staining. (A) Wild type 
and Cx43-ablated REKs expressing GFP-tagged Cx31, as well as L209F, L135V and 
I141V mutants (green) were immunolabeled for BiP (red) to highlight cells undergoing 
ER stress, and stained with Hoechst (blue) to denote nuclei. The L209F and L135V 
mutant-expressing cells exhibited less BiP staining compared to neighboring 
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4.0 – Discussion 
 
4.1 – Examining the life-cycle of Cx31 and characteristics of EKVP-linked 
Cx31 mutants in rat epidermal keratinocytes  
 
Of the five epidermal connexins linked to skin disease, Cx31 remains one of the more 
poorly studied connexins. Cx43, Cx30 and Cx26 have been extensively characterized due 
to the many mutations that they harbor, and their link to a variety of diseases and 
disorders (Lilly et al., 2016). Cx31, on the other hand, has been identified in only EKVP 
(Ishida-Yamamoto, 2016), and studies on its life cycle and role in keratinocytes remains 
limited. Moreover, it remains unclear whether Cx31 assembles into gap junctions with 
the co-expressed Cx26, Cx30 and Cx43, or whether Cx31 assembly into gap junctions is 
governed by the highly expressed Cx43. Since the linkage between EKVP and Cx31 was 
first established in 1997 (Richard et al., 1997), at least 14 different Cx31 mutations have 
been identified in EKVP patients (Fuchs-Telem et al., 2011; Gottfried et al., 2002; Ishida-
Yamamoto, 2016). The mechanisms of how Cx31 mutants cause disease remain poorly 
understood, and whether mutants cause a loss or gain-of function is not fully elucidated. 
This study, therefore, investigates the life cycle of Cx31 in keratinocytes and its co-
assembly with Cx26, Cx30 and Cx43 into gap junctions. We hypothesized that a) the 
wild type Cx31 exhibits a similar life-cycle as Cx43 in keratinocytes, and that b) the 
EKVP-linked Cx31 mutants, L209F and L135V, will fail to form gap junctions to 
promote keratinocyte cell death. Our data does not support our hypothesis that wild type 
Cx31 exhibits a similar life-cycle as Cx43 in keratinocytes. Rather, our results show that 
the apparent half-life of Cx31 in gap junctions is longer compared to Cx43, and Cx31 gap 
junctions persist at the cell surface longer than Cx43. Our data, does however, support 
our hypothesis that the EKVP-linked L209F and L135V mutants will fail to form gap 
junctions to promote cell death. Our observations also reveal that Cx31 gap junctions are 
highly dynamic and that Cx43-ablation does not prevent their assembly into gap 
junctions. Lastly, when co-expressed, wild type Cx31 exhibits differential localization 
patterns with Cx26, Cx30 and Cx43 in gap junctions.  
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4.2 – Cx31 exhibits a longer ‘apparent’ half-life compared to Cx43 in 
keratinocytes 
 
Until recently, a number of pulse-chase studies had established most connexins as short-
lived proteins, with a half-life of 1 – 5 hours in the heart and liver (Beardslee et al., 1998; 
Fallon and Goodenough, 1981; Laird et al., 1991). Understandably, connexins  may have 
shorter half-lives to respond quickly to changes in  homeostasis, particularly in the heart, 
where rapid connexin turnover may be a method to regulate GJIC to meet the varying 
physiological demands of cardiac cells (Beardslee et al., 1998). However, Kelly and 
colleagues recently assessed the projected half-life of Cx30 and found that it had  a 
prolonged half-life of >12 hours in keratinocytes  (Kelly et al., 2015). Cx30 is expressed 
in the skin and cochlea and it has been suggested that a slow turnover rate would 
conserve  the cellular energy required for rapid gap junction internalization and 
degradation  (Kelly et al., 2015). Not unlike Cx30, our cycloheximide and BFA studies 
strongly point to a longer half-life for Cx31 compared to Cx43 in keratinocytes. 
Additionally, Cx31 gap junctions were found to persist at the cell surface longer than 
Cx43 gap junctions. In another report, a pulse-chase study determined the half-life of 
Cx31 to be 4.1 hours in HeLa cells (Diestel et al., 2004), which is still longer than Cx43 
where it has been reported to be ~2 hrs (Hunter et al., 2005). It is possible that the relative 
half-life of Cx31 in keratinocytes is greater than that in HeLa cells because keratinocytes 
undergo highly coordinated processes in the epidermis that include proliferation, 
differentiation and migration. Within the epidermis, the highest Cx31 expression levels 
are found within the stratum granulosum layer (Di et al., 2001). At this cellular stage, 
keratinocytes initiate the formation of the cornified envelope, a structure essential for 
proper epidermis formation  and necessary to establish barrier function (Menon, 2002). 
As such, a prolonged half-life of Cx31 gap junctions may be necessary to maintain a high 
level of GJIC between the keratinocytes engaged in the cornification process.  
This raises the question as to what passes through Cx31 channels that is essential for a 
healthy epidermis? Unfortunately, to-date, there has been no analytical interrogation of 
what metabolites specifically pass through Cx31 channel pores. However, in general, 
  55 
 
Ca2+ ions are known to play a role in epidermal function (Bosen et al., 2015; Menon and 
Elias, 1991). Specifically, it is thought that the cornification process is triggered by a 
large influx of Ca2+ in the stratum granulosum and that perturbations in the Ca2+ gradient 
are associated with rare skin disorders such as KID syndrome and the more commonly 
occurring skin disorder, psoriasis (Bosen et al., 2015; Menon, 2002; Menon and Elias, 
1991). Since Cx43 and Cx26 have short half-lives (Beardslee et al., 1998; Fallon and 
Goodenough, 1981; Laird et al., 1991), the responsibility of creating and maintaining a 
large Ca2+ concentration in the stratum granulosum may fall on the long-lived Cx31 and 
Cx30 gap junction proteins. In addition to Ca2+, a class of small-molecules, 2-(3,4,5-
trimethoxyphenylamino)-pyrrolo[2,3-d] pyrimidines, have been identified as facilitators  
of primary normal human epidermal keratinocyte differentiation (Hong et al., 2007). 
Since the scope of the gap junction-mediated transfer of metabolites remains poorly 
understood  (Goldberg et al., 1999, 2004), it can only be speculated that the 2-(3,4,5-
trimethoxyphenylamino)-pyrrolo[2,3-d] pyrimidines molecules have the potential to pass 
through gap junction channels since they meet the <1 kDa size criteria.  
4.3 – Cx31 may interact with Cx30 in gap junctions 
 
The co-expression of multiple connexins within the same keratinocytes has prompted a 
number of studies that specifically examine the localization pattern of different connexins 
that reside within common  gap junction structures, namely; Cx26 and Cx43, Cx30 and 
Cx43, and Cx26 and Cx30 (Ahmad et al., 2003; Gemel, 2004; Kelly et al., 2015). Here, 
some connexins were found to fully intermix with other connexins (Cx26/Cx30) while 
other connexins partition into subdomains of a gap junction plaque (Cx26/Cx43 or 
Cx30/Cx43) (Ahmad et al., 2003; Gemel, 2004; Kelly et al., 2015). This suggests that 
some connexins (Cx26 and Cx30) may coexist within the same connexons consistent 
with their co-immunoprecipitation (Yum et al., 2007). Our high-resolution imaging, 
together with correlation coefficient analysis, revealed that Cx31 formed separate 
subdomains with plaques that also contained Cx26 and Cx43. However, Cx31 and Cx26 
exhibited a higher correlation coefficient raising the possibility that they had co-
assembled into common connexons, but this has yet to be directly demonstrated.  Since it 
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has been shown that Cx31 co-immunoprecipitates and forms heterotypic channels with 
Cx26 in mouse epidermis, our findings would agree with this possible interaction 
between Cx31 and Cx26 (Tang et al., 2015). The long-lived Cx31 and Cx30 exhibited the 
highest correlation coefficient when co-assembled into the same gap junctions suggesting 
a possible interaction between these two connexins within the same connexons. Although 
the ability of Cx31 and Cx30 to form heteromeric connexons in keratinocytes remains 
uninvestigated, studies have shown the co-immunoprecipitation and formation of 
heterotypic channels between Cx31 and Cx30 in mouse epidermis and HeLa cells 
(Abrams et al., 2006; Tang et al., 2015). The benefit of co-assembled Cx26 and Cx30 gap 
junctions in GJIC has been documented in the cochlea, where heteromeric gap junctions 
are thought to be more effective at  transferring  Ca2+ compared to homotypic Cx26 and 
Cx30 gap junctions (Sun et al., 2005). Likewise, we speculate that co-assembled Cx31 
and Cx30 gap junctions may be more efficient in meeting the Ca2+ demands of the 
stratum granulosum than their homotypic counterparts. It has been suggested that  Cx31 
and Cx30 are co-regulated at the translational level, and perhaps even at the 
transcriptional level to co-assemble into gap junctions (Tang et al., 2015).    
4.4 – Cx31 gap junctions are dynamic and undergo fission and fusion events 
 
Through X-ray crystallography and electron micrograph analysis, gap junctions were  
described originally as semi-crystalline lattice structures (Caspar et al., 1977; Severs, 
1995) suggesting that they may be static structures with little mobility within the cell 
membrane.  Today, through studies that have focused on Cx26, Cx32 and Cx43, it is well 
understood that gap junction plaques are quite dynamic in nature as these structures 
undergo fusion, fission, and movement within the membrane (Simek et al., 2008; Thomas 
et al., 2005; Windoffer et al., 2000). Following suit, our results revealed that Cx31 gap 
junctions are dynamic as they also undergo fission and fusion events. In addition to this, 
many gap junctions were observed to change shape and display slight erratic movements. 
It is possible that the relatively short ~60 amino acid C-terminal tail of Cx31 
(UniProtKB-O75712) permits a limited number of Cx31-protein interactions, thereby 
allowing greater gap junction dynamics, compared to the >40 proteins that have been 
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reported to directly or  indirectly interact with the 151 amino acid C-terminal tail of Cx43 
(UniProtKB-17302) (Ambrosi et al., 2016; Axelsen et al., 2013; Sorgen et al., 2018). 
Thus, Cx31 would be expected to be devoid of direct interactions with several scaffolding 
and structural proteins, such as beta-tubulin and drebrin, which are thought to aid in the 
stabilization of Cx43 gap junctions (Ambrosi et al., 2016; Butkevich et al., 2004; 
Giepmans et al., 2001). The beta-tubulin binding motif is exclusively found in Cx43, and 
as of yet, has not been identified in any other connexin, including Cx31 (Giepmans et al., 
2001). However, the relatively short C-terminal tail of Cx32 has also been shown to 
promote static gap junctions (Katoch et al., 2015). The deletion of the 69 amino acid C-
terminal tail of Cx32 resulted in increased gap junction movement and fusion events 
compared to wild type Cx32, implicating the role of a shorter C-terminal tail in 
promoting static gap junctions (Katoch et al., 2015). Additionally, phosphorylation of the 
Cx31 C-terminal tail has been implicated in inhibiting Cx31 degradation in HeLa cells 
(Diestel et al., 2004). It is therefore possible that phosphorylation protects Cx31 from 
degradation, thus promoting the persistence of gap junctions at the cell surface and 
allowing for more opportunity for gap junction plaques to remodel. Overall, a longer 
Cx31 life expectancy at the cell surface could serve to maintain high levels of Cx31 GJIC 
to meet the nutrient demands of keratinocytes.  
4.5 – Cx43 does not play a role in the ability of Cx31 to form gap junctions 
 
Two or more connexin family members  are co-expressed in almost every tissue of the 
adult body suggesting they likely serve unique, as well as overlapping roles (Laird, 
2006). However, these roles remain incompletely defined and completely unexplored for 
some connexins.  Additionally, the relationship between co-expressed connexin family 
members in the epidermis remains poorly understood. Kretz and colleagues were able to 
provide some insight into this relationship through the use of an inducible cre-mediated 
deletion of Cx43 mouse model (Cx43Cre-ER(T)/+) (Kretz et al., 2003). In this Cx43-reduced 
mouse wounding model, both Cx31 and Cx30 levels reached a maximum expression 2 
days post-wounding, as opposed to 3 days post-wounding in wild type mice (Kretz et al., 
2003). Furthermore, overall Cx31 levels in the epidermis was increased in these mutant 
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mice (Kretz et al., 2003) suggesting that Cx31 expression was upregulated to compensate 
for the reduction in Cx43. To further investigate the relationship between Cx43 and 
Cx31, we generated Cx43-ablated REKs and found that Cx31-GFP continued to form 
numerous gap junctions even in the absence of Cx43. The Cx31-GFP gap junctions 
formed in Cx43-ablated REKs were comparable to those found in wild type REKs 
suggesting that Cx43 played no role in the ability of Cx31 to form gap junctions. 
Moreover, these Cx43-ablated REKs displayed no noticeable morphological changes or 
changes in K14 distribution suggesting that Cx43-ablation did not appear to change the 
differentiation state of the cell. This was unexpected since it has been shown that a Cx43-
knockdown in REKs leads to a disruption in organotypic epidermis formation (Langlois 
et al., 2007). Furthermore, Cx43 has been implicated in the misregulation of keratinocyte 
proliferation (Sutcliffe et al., 2015). An intense upregulation of Cx43 was observed in 
hyperproliferative keratinocytes surrounding the wound edges of diabetic foot ulcers and 
venous leg ulcers compared to unwounded forearm skin (Sutcliffe et al., 2015).  Based on 
this, it could be presumed that a loss of Cx43 would elicit a premature onset of 
keratinocyte differentiation. However, this was not the case in our Cx43-ablated REKs 
and it is therefore possible that the effects of Cx43-ablation are only apparent in 
keratinocytes that have already entered the differentiation program.  
4.6 – The EKVP-linked L209F and L135V mutants induce apoptosis in 
keratinocytes 
 
EKVP is characterized by hyperkeratotic plaques and erythematous patches (Richard et 
al., 2003). Clinical treatments focus on alleviating symptoms through the use of topical 
retinoids, emollients or keratolytic therapy, however, only hyperkeratotic plaques  
improve with treatment  while erythematous patches typically persist (Luy et al., 1988; 
Richard et al., 2003). These erythematous patches cause great discomfort as they can be 
accompanied by a burning or stinging sensation. Oral retinoids such as vitamin A, 
acitretin, and etritinate have also been shown to improve symptoms (Graham-Brown and 
Chave, 2002; Shizukawa et al., 2015). However, the use of such drugs in children 
remains a subject of controversy as they have been implicated in growth retardation, and 
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in the case of etritinate, is a teratogenic drug (Shizukawa et al., 2015). Therefore, the use 
of oral and topical retinoids may not be the most suitable treatment for EKVP patients, a 
majority of whom develop symptoms early on in childhood. Targeting of connexin 
proteins may be more beneficial for therapeutics since, to date, mutations in Cx31, 30.3 
and Cx43 have been identified in EKVP patients with at least fourteen of them in Cx31 
(Fuchs-Telem et al., 2011; Gottfried et al., 2002; Ishida-Yamamoto, 2016; Lilly et al., 
2016). To date, identified Cx31 mutants include; G12R, G12D, G12S, C86S, L135V, 
L209F, F137L, L34P, R42P,T202D, E100K, V30I, G45E and E47D; five of which 
(G12D, G12R, C86S, L34P, R42P) have been ectopically expressed  and found  to 
exhibit  cytoplasmic localization in HeLa cells, NEB1 keratinocytes, or NTERT cells 
(Fuchs-Telem et al., 2011; Glatz et al., 2011; Gottfried et al., 2002; Ishida-Yamamoto, 
2016). In one study, Cx31 F137L heterozygous mutant mice were generated in an attempt 
to model EKVP (Schnichels et al., 2007). However, these mice exhibited mostly normal 
epidermis, with only approximately 5% of the tail skin showing hyperproliferation, and 
no erythematous areas. No differences in the expression pattern or level of Cx26, Cx31, 
Cx30 and Cx43 were observed in the epidermis and unfortunately, the  localization of 
connexins in keratinocytes of the F137L mice were not examined (Schnichels et al., 
2007). Furthermore, there has been no visual evidence of cell death in either patient or 
mouse hyperproliferative skin (Fuchs-Telem et al., 2011; Morley et al., 2005; Schnichels 
et al., 2007).  
To investigate further the mechanisms of how Cx31 mutations lead to EKVP, we 
examined the Cx31 EKVP-linked mutants L209F and L135V, and, as a non-EKVP 
causing control mutant, the deafness-linked I141V mutant. The L209F mutation is found 
within the C-terminal tail, while the L135V and I141V mutations are found within the 
third transmembrane domain of the Cx31 polypeptide (Liu et al., 2000; Morley et al., 
2005; Scott et al., 2010). We found that the L209F and L135V mutants failed to form gap 
junctions and induced apoptosis in REKs, while the I141V mutant formed gap junctions 
similar to wild type Cx31. These findings are in-line with other EKVP-linked Cx31 
mutants (G12D, G12R, C86S, L34P and R42P) that cause  a loss-of- channel function 
through their failure to form gap junctions, and induce cell death (Di et al., 2002; He et 
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al., 2005; Tattersall et al., 2009). Interestingly, one EKVP-linked Cx31 mutant, R42P, 
was  observed to form hemichannels that were able to allow  the passage of ATP  in 
HeLa cells (Chi et al., 2012). The R42P mutant expressing cells also exhibited increased 
ROS production (Chi et al., 2012). There is  increasing evidence that EKVP-linked Cx31 
mutants induce apoptosis through ER stress (Chi et al., 2012; Tang et al., 2015; Tattersall 
et al., 2009). Thus, we predicted that the expression of the L209F and L135V mutants 
would increase the levels of the ER stress reporter protein, BiP. However, we found that 
the L209F and L135V mutant expressing cells did not exhibit more BiP staining, but 
rather, less staining compared to neighbouring untransfected cells. It is possible that the 
Cx31 L209F and L135V mutants are so potent at inducing ER stress that even 1 day after 
introducing the mutants the cells have progressed extensively into the apoptotic pathway 
such that membrane integrity was lost and BiP leaked from the cells. However, even if 
the L209F and L135V mutants are driving keratinocytes into a cell death pathway, it 
remains unclear how cell death may lead to the thickening of cellular layers in 
hyperkeratotic plaques, as frequently observed in EKVP patients. Clearly more studies 
are needed to understand the root of this process. Cx31 mutant-driven cell death, 
however, may explain the formation of erythematous patches, also frequently observed in 
EKVP patients. Erythematous patches are accompanied by inflammation and are 
transient, as they are easily triggered by factors such as temperature and emotional stress 
(Morley et al., 2005; Scott et al., 2010). Cx31 L209F and L135V mutant-induced 
apoptosis could perhaps trigger the release of proinflammatory molecules which lead to 
the formation of erythematous patches.   
4.7 – Limitations and future studies  
 
We have shown that the apparent half-life of Cx31 in gap junctions is longer compared to 
Cx43. However, our in vitro results should be interpreted carefully since the half-life of 
connexins may differ between undifferentiated and differentiated keratinocytes. 
Therefore, the half-life of Cx31 within mouse epidermis should be investigated through 
pulse-chase studies. Our colocalization studies in vitro can only suggest that Cx31 may 
interact with Cx30 but does not provide evidence as to whether a true molecular 
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interaction actually occurs. However, the possible interaction between Cx31 and Cx30 is 
supported by the co-immunoprecipitation of Cx31 and Cx30 in mouse epidermis which 
suggested the formation of heterotypic channels (Tang et al., 2015). To investigate 
whether Cx31 and Cx30 form heteromeric connexons in epidermis, future co-
immunoprecipitation studies should incorporate the solubilization of gap junctions in 
dodecyl maltoside (Diez et al., 1999)  as a means to break the non-covalent bonds in gap 
junction channels and release the connexons. To determine the function and selectivity of 
Cx31 and Cx30 heterotypic/heteromeric gap junction channels and whether they are more 
efficient in GJIC compared to their homotypic counterparts, in vitro dye transfer studies 
such as fluorescence recovery after photobleach using calcein-AM dye (MW 623 Da) and 
microinjection studies using Alexa fluor 350 (MW 410 Da), should be conducted on 
connexin-deficient HeLa cells co-transfected with Cx31 and/or Cx30. The use of protein 
overexpression systems however, bears limitations including the potential to promote 
unwanted protein interactions, saturation of the secretory pathway and aggregate 
formation (Ma et al., 2010; Moriya, 2015; Stoebel et al., 2008). Despite these limitations, 
in vitro studies still provide insight into the cellular characteristics of Cx31 in REKs that 
should inform on the human tissue. Therefore, further in vitro studies will enhance our 
understanding of the interaction and function of gap junctions co-assembled by Cx31 and 
Cx30, and whether they are more efficient in GJIC for epidermal homeostasis.  
Fixed hyperkeratotic and transient erythematous patches are hallmark characteristics of 
EKVP (Richard et al., 2003). From histological examination of the hyperproliferative 
plaques, it can be suggested that the thickening of the epidermis is due to the 
hyperproliferation of keratinocytes (Fuchs-Telem et al., 2011; Morley et al., 2005). 
However, similar to other Cx31 mutants in vitro (Di et al., 2002; He et al., 2005; 
Tattersall et al., 2009), we found that the Cx31 L209F and L135V mutants do not form 
gap junctions in REKs, but do cause cell death. While our findings align with Cx31 
mutants G12D, G12R, C86S, L34P and R42P (Di et al., 2002; He et al., 2005; Tattersall 
et al., 2009), this does not provide clear insight into why EKVP patients present with  
hyperproliferative and erythematous skin (Fuchs-Telem et al., 2011; Morley et al., 2005). 
Therefore, why cell death is induced by Cx31 mutants L209F and L135V in vitro is 
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unclear. Labeling of additional ER stress markers such as CHOP, elF2a or spliced XBP-1 
would be useful to further investigate whether the Cx31 mutants induce apoptosis 
through ER stress. In the Cx31 F137L heterozygous mutant mice, there was no evidence 
of cell death in hyperkeratotic plaques (Schnichels et al., 2007). Therefore, the use of the 
Cx31 F137L mouse model to examine the distribution of mutant Cx31 with co-expressed 
Cx26, Cx30 and Cx43 in hyperproliferative keratinocytes should help elucidate whether 
EKVP-linked Cx31 mutants cause a loss or gain-of function in vivo. Additionally, Ca2+ 
concentrations within the hyperproliferative epidermis can be measured to determine 
whether a disrupted Ca2+ gradient contributes to the EKVP phenotype. Together, these 
studies will provide clarity into the mechanisms of how Cx31 mutants cause disease and 
whether they interact with co-expressed Cx30, Cx43 and Cx26 to disrupt the Ca2+ 
gradient in hyperproliferative and erythematous skin. 
In summary, this study has revealed the apparent half-life of Cx31 in gap junctions is 
longer compared to Cx43, and that Cx31 gap junctions persist at the cell surface longer 
than Cx43. Furthermore, we have shown that Cx31 gap junctions are dynamic and that 
within these gap junctions, Cx31 may interact with Cx30. However, our findings on the 
EKVP-linked Cx31 mutants L209F and L135V in REKs revealed that they cause cell 
death but it is not clear how this relates to EKPV. Since current treatment options for 
EKVP patients remain controversial due to their side effects and their implications in 
growth retardation and teratogenesis (Graham-Brown and Chave, 2002; Shizukawa et al., 
2015), a greater understanding of Cx31 in epidermal homeostasis and its pathophysiology 
in EKVP is required  for the development of  Cx31-targeted therapeutics. The 
development of several pharmaceutical products including Nexagon®, an antisense 
oligodeoxynucleotide that acts to destroy Cx43 mRNA and PeptagonTM, a 
peptidomimetic that blocks Cx43 hemichannels, provide hope that a successful 
therapeutic will be found by companies like CoDa Therapeutics, Inc. Both Nexagon® and 
PeptagonTM have been shown to improve wound healing, inflammation and scarring 
(Becker et al., 2016). Therefore, with further intensive research into the role of Cx31 in 
the epidermis, the development and commercialization of Cx31-targeted therapies remain 
a viable hope for EKVP patients.    
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